Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Phase 4 Completed 200 enrolled Novartis Pharmaceuticals

Non-randomizedCrossoverSingle-blindTreatment

Summary

This study will evaluate the impact that GI complaints have on patient-reported outcomes and to determine if there is improvement in patient-reported outcomes when converted from mycophenolate mofetil (MMF) to Enteric-coated mycophenolate sodium (EC-MPS)

Timeline

Start: 2006-12
Primary completion: 2007-06
Completion: —

Publications

Background Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. J Korean Med Sci. 2010 Dec;25(12):1759-65. doi: 10.3346/jkms.2010.25.12.1759. Epub 2010 Nov 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mycophenolate Sodium	Unknown	—	—

Indications

No indication recorded.